• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CSL
Click for more information
1.01% $297.89

CSL LIMITED

Market Cap $142.5B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus... CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others. More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
CSL
USD adr at one year high 		00:59 0 157
00:59 Last post  W534220 Comments Created with Sketch.  0  Views Created with Sketch.  157 
CSL
Still growth in idelvion 		03/07/24 0 157
03/07/24 Last post  W534220 Comments Created with Sketch.  0  Views Created with Sketch.  157 
CSL
Ann: Notification of cessation of securities - CSL 		03/07/24 0 208
03/07/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  208 
CSL
News: CSL UPDATE 3-Bird flu concern prompts US to award Moderna $176 million for vaccine development 		03/07/24 0 220
03/07/24 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  220 
CSL
News: CSL US awards Moderna $176 million to produce bird flu vaccine 		02/07/24 1 426
02/07/24 Last post  optimistus Comments Created with Sketch.  1  Views Created with Sketch.  426 
CSL
CSL - $300 and beyond
2
27/06/24 92 52K
27/06/24 Last post  W534220 Comments Created with Sketch.  92  Views Created with Sketch.  52K 
CSL
Hemgenix rollout 		27/06/24 0 270
27/06/24 Last post  W534220 Comments Created with Sketch.  0  Views Created with Sketch.  270 
CSL
News: CSL UPDATE 1-Finland to start bird flu vaccinations for humans 		25/06/24 0 206
25/06/24 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  206 

See All Discussions arrow Created with Sketch.

Timeline

Notification of cessation of securities - CSL
03 Jul 14:08
 
Notification of cessation of securities - CSL
05 Jun 11:37
 
Notification of cessation of securities - CSL
03 May 12:12
 
Shareholder Information Meetings
23 Apr 09:58
 
CSL Australia Investor Site Tour Presentations
11 Apr 08:25
 
Publication of AEGIS II Trial Data
08 Apr 08:33
 
View More arrow Created with Sketch.

Featured News

NEWS Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker
right-arrow Created with Sketch.
BIO Biome posts record sales revenue of $13M in FY24 – up 80% vs pcp and higher than forecast
right-arrow Created with Sketch.
LRV Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%
right-arrow Created with Sketch.
NEWS Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25
right-arrow Created with Sketch.
ARU Cashed up Arafura locks in $171M German export agency deal; locks in NdPr offtake for wind turbines
right-arrow Created with Sketch.
EMD Emyria and UWA secure $499,411 grant to advance MDMA analogue drug program
right-arrow Created with Sketch.
(20min delay)
Last
$297.89 		Change
2.990(1.01%) 		Mkt cap ! $142.5B
Open High Low Value Volume
$297.44 $299.00 $297.16 $38.98M 130.8K

Buyers (Bids)

No. Vol. Price($)
2 8 $297.87
 

Sellers (Offers)

Price($) Vol. No.
$297.91 79 5
View Market Depth
Last trade - 11.04am 04/07/2024 (20 minute delay) ?
Last
$297.90 		  Change
2.990 ( 1.15 %)
Open High Low Volume
$297.33 $298.98 $297.33 8809
Last updated 11.24am 04/07/2024 ?
CSL (ASX) Chart

Top Stories

Alkane Resources hit 57.2Kozpa gold production through FY24 – and eyeing 70Ktpa in FY26

Alkane Resources has announced its gold production metrics for full year FY24 coming in at 57,217oz – brushing just short of upper guidance.
ACCC raises competition concerns about acquisition of Lendlease projects The ACCC has published a Statement of Issues on competition risks posed by the intended acquisition of 12 residential community projects.
XReality Group wins $800K contract from Aus Government for military and police VR training tech xReality Group has announced its receipt of an $800K contract from to provide its Virtual Reality (VR) training tech.
Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring Sun Silver executive director Gerard O'Donovan discusses a 6,216 grams Fort Intercept at the Maverick Spring Silver Project from historical data and drill assessments.
Swagman shoot proves plentiful for AIC, with Cu beyond 3% close to Eloise AIC Mines Ltd has progressed drilling at its Swagman discovery in Queensland, finding copper grading beyond 3 percent.

Featured News

AVA Ava Risk Group expands US presence with A$0.7M Substation Deal
right-arrow Created with Sketch.
LRV Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%
right-arrow Created with Sketch.
AHK Ark Mines defines significant exploration target at Sandy Mitchell rare earths project
right-arrow Created with Sketch.
EX1 Tryptamine Therapeutics completes maiden dosing of IV psilocin – a global first
right-arrow Created with Sketch.
BIO Biome posts record sales revenue of $13M in FY24 – up 80% vs pcp and higher than forecast
right-arrow Created with Sketch.
EMD Emyria and UWA secure $499,411 grant to advance MDMA analogue drug program
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.